Key Points This investment has averaged annual gains of close to 13% over the past 15 years. It encompasses many healthcare stocks -- including superperformer Eli Lilly. It's a promising investment if you're bullish on the healthcare sector. 10 stocks we like better than Vanguard World Fund - Vanguard Health Care ETF › If a millennial were to ask me what healthcare stock they might buy in order to get rich, I could think of several to name. But as with most stocks, I couldn't be confident that ...

Pfizer TodayPFEPfizer$23.75 +0.15 (+0.64%) 52-Week Range$20.92▼$30.43Dividend Yield7.24%P/E Ratio12.63Price Target$28.12Add to WatchlistIn the United States' healthcare sector, a new growth theme is emerging that nearly all companies want to capitalize on. Like artificial intelligence for technology stocks, weight loss drug manufacturing and distribution businesses are all the hype for this new growth wave taking over the industry. That said, there are two ways for businesses to capitalize on this opportun ...

What is the difference between risk and uncertainty. Under conditions of risk, we know what might happen and we know roughly how likely each outcome is. Under conditions of uncertainty, we don't know the possible outcomes and we can't assign probabilities to them.It's not exactly ideal. So, are insurers longing for risk. Impactful changes, both large and small, are transforming the way our global systems operate.For example, weight loss drugs. The new market for GLP1 or obesity drugs is forecasted to reach ...

Investors once speculated that Pfizer might consider acquiring Viking.Weight loss drugs have represented an enormous growth area for biotech and pharma companies over the past couple of years. Pharma giants Eli Lilly and Novo Nordisk dominate the market with their drugs and have brought in billions of dollars in revenue as demand skyrocketed. In fact, last year demand was so high -- surpassing supply at certain points -- that these drugs were on the U.S. Food and Drug Administration's drug shortage list.Sin ...

Oracle ( ORCL ) has confirmed it will run TikTok US; is naming two CEOs to accommodate the handoffFed Governor Stephen Miran, the 'lone dot' on the Fed Dot Plot, said that Fed rates should be 2.00% lower in his first public speech post-FOMC.The index went from 6,200 to 6,300 in just 15 trading days. From there, it went to 6,400 in 17, 6,500 in 13, and 6,600 in 12. If it were to hit 6,700 today, it would have done so in just 6 trading days.The S&P 500 is sitting just off intraday highs, inching closer and cl ...

Let's get to Jim and stop trading. One of my favorite executives is David Ricks from Eli Liy. He came on after that last trial and that was the uh a trial for weight loss obviously August 7225.He said look our stocks shouldn't be down that much. I mean there's a lot more things in the pipeline. He then bought 1,632 shares at 645 uh August 12th.He said saying basically look we're we're not bad. Well, of course, the new tri another trial came out today, August 26. Same kind, the misinformation thing is so leg ...

Core Insights - Hims & Hers is experiencing rapid revenue growth but is currently facing a legal battle that poses risks to its future performance [1][4] - The company's stock has seen a significant decline of 17% this week and is down 25% from its all-time highs, despite a remarkable 400% increase over the past five years [1][2] Financial Performance - In Q2 2025, Hims & Hers reported a 73% year-over-year revenue growth, exceeding $500 million, driven by a 30% increase in total subscribers and a 30% rise in spending per active subscriber [2] - The company has achieved $2 billion in trailing revenue, marking an increase of over 1,000% in the last five years, solidifying its position as a leading telehealth provider [6] Legal Challenges - Hims & Hers is embroiled in a legal dispute with Novo Nordisk, stemming from allegations of selling knockoff weight loss drugs after a partnership ended due to disagreements [3][4] - The company is accused of illegally selling patented weight loss drugs at a discount now that the shortage has resolved, raising concerns among investors about the potential impact on future revenue and profitability [3][4] Market Position - Hims & Hers has made significant market share gains in the telehealth sector, particularly in the online provision of drugs and medical treatments [6] - Despite its strong growth trajectory, the ongoing legal issues may deter potential investors from buying the stock at its current dip [7][8]

Your next guest warned you about a red-hot stock a few months ago, but only if you listened. And then on Monday, Hims and Hers crashed, tanking 30% after Novo Nordisk accused the company of deceptive marketing. Hims and Hers, of course, denies it.You guys talked about it in the one:00 show, Kelly. But let's find out what Herb Greenberg may have seen that others didn't. Herb, of course, a CNBC contributor.He raised a red flag on Hims back in February and he joins us now on the the Herb hotline as we're now g ...

Core Insights - The stock price of Novo Nordisk has significantly decreased after a strong performance in 2024, but it is expected to recover and grow further in the coming years [1] Industry Overview - The obesity rate in the U.S. has more than doubled from 1990 to 2022, rising from slightly over 21% to nearly 44% [2] - Globally, obesity affected over 1 billion people in 2022, leading to an expected surge in sales of weight loss drugs, which exceeded $30 billion worldwide for the first time in 2024 [3] - Morgan Stanley has revised its forecast for weight loss drug sales in 2030 from $77 billion to a range of $105 billion to $144 billion, indicating a potential threefold increase in less than a decade [4] Competitive Landscape - Novo Nordisk and Eli Lilly are the leading companies in the U.S. weight loss drug market, with Eli Lilly's Zepbound as a notable competitor [5] - The approval process for new medications in major markets like the U.S. and the EU is lengthy, giving established products like Wegovy an advantage [6] - Even if Novo Nordisk faces competition from Eli Lilly or new entrants, it is likely to maintain a significant market share in a rapidly growing industry [6]